The Scrambler Therapy® device ST-5A (Made in Italy) replaces the previous model MC-5A
Scrambler Therapy® Technology ST-5A is a U.S. FDA 510(k)-cleared (#K201458 for Delta International Services & Logistics) and European Medical Devices Regulation CE mark-certified (#CE 0051)
This therapy was born from the start to treat chronic neuropathic and oncological pain, and in particular forms refractory to other therapies and opioids. For this reason, the substantial totality of the clinical studies published on this therapy before and after the placing on the market specifically concerns this type of pain.
The Scrambler Therapy® device has been used to successfully treat thousands of patients worldwide, where it has been shown to be effective in treating neuropathic and oncologic pain. Scrambler Therapy® Technology ST-5A is a stand-alone medical electroanalgesia device, and does not require combinations with other analgesic therapies. This medical device has been developed in Italy by Prof. Giuseppe Marineo.
In the Scrambler Therapy®, the therapeutic approach is no longer to inhibit the transmission of pain, but to transform the information of pain into “non-pain” using the same pathways. In the Scrambler Therapy® model, information becomes the central point of control of the plasticity of the pain system, both in the genesis of chronicity (induced by endogenous information of pain repeated over time) and in its regression (induced by synthetic information of “no pain” repeated over time). The result of this theoretical model applied in the Scrambler Therapy® medical device, is an immediate and complete analgesic effect in treatment, and the return to normal physiological response after one or more cycles of treatment. In view of these specific approach, it is quite clear that the concept of similarity that only considers the parameters of frequency, pulse width and intensity (used in other devices) for this Technology is not applicable because they do not generate and do not characterize the specific information of “no pain” of the Scrambler Therapy®. In this sense any modification of the emissions of the Scrambler Therapy in the form and organization of the flows in time (i.e. the specific strings of "no pain" information), is functionally equivalent to the modification of the chemical formula of a drug.
Scrambler Therapy® if correctly used is a control tool for severe chronic neuropathic and cancer pain. Scrambler Therapy® is very effective, non-invasive and mainly to be used in ambulatory care and hospital facilities. If carried out correctly the analgesic effect during the treatment is very rapid. In just a couple of seconds the pain perception completely disappears. This is true even in cases where pain is of high intensity and non responsive or poorly responsive to opioids or other electro-analgesia devices such as TENS or implanted devices. Short- and long-term effects of a single treatment cycle depend on the type of pathology and other variables. In most cases of benign pain one treatment cycle is enough to produce pain relief for at least two months, but can even exceed 12 months if neuropathic damage is limited (mono-radicular) or the pathology has no evolution feature. Other variables that influence the treatment outcome are pharmaceutical interactions. Immediate analgesic efficacy during the treatment is a constant factor regardless of pathology and pain intensity.
For more information visit the Official Scrambler Therapy® scientific and clinical information website .
DIS&L through its law firm is the only company authorized to sign international exclusive agreements in all international area , provide maintenance and distributor support for method usage training and other logistics needs. To request a national exclusive agreement the candidate distributor must have minimum requirements listed on the “ Distributor Requirement ” page. Indications
Copyright © DIS&L. All rights reserved